Drug intelligence / Profile preview

Jianyao Migu (HUTCHMED)

Development stage: Unknown
Lead developer: Shanghai Hutchison Pharmaceuticals
Administration: Oral

Overview

Jianyao Migu is a Traditional Chinese Medicine (TCM) formulation developed by Shanghai Hutchison Pharmaceuticals for the treatment of osteoporosis and osteoporotic low back pain. It is specifically indicated for patients presenting with the kidney deficiency and blood stasis syndrome type, according to TCM diagnostic criteria. The drug is currently being evaluated in Phase II clinical trials to assess its efficacy and safety in elderly patients, with the goal of establishing a clinical basis for Phase III development. As a botanical product, its therapeutic effects are intended to tonify the kidney and promote blood circulation to improve bone density and alleviate pain associated with osteoporotic conditions.

Brand names: Jianyao Migu Tablet
Other names: Jianyao Migu Tablet健腰密骨片

Beyond the preview

Go deeper on Jianyao Migu (HUTCHMED).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jianyao Migu (HUTCHMED).

Explore the full profile